Skip to Main Content
Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 2023, Issue 1
December 8 2023
Issue Cover
In this Issue

Table of Contents

Ham-Wasserman Lecture

Thrombotic anti-PF4 immune disorders: HIT, VITT, and beyond
Andreas Greinacher,Theodore E. Warkentin
View Articletitled, Thrombotic anti-PF4 immune disorders: HIT, VITT, and beyond

Acquired Hemophilia A Diagnosis and Management

Diagnosis and laboratory monitoring of acquired hemophilia A
Sean Platton,Suthesh Sivapalaratnam,Priyanka Raheja
View Articletitled, Diagnosis and laboratory monitoring of acquired hemophilia A
Immunotherapy of acquired hemophilia A
Andreas Tiede
View Articletitled, Immunotherapy of acquired hemophilia A
The role of emicizumab in acquired hemophilia A
Jacqueline Poston,Rebecca Kruse-Jarres
View Articletitled, The role of emicizumab in acquired hemophilia A

Alphabet Soup: Challenging Consults on the Pediatric Units

Inflamed—HLH, MAS, or something else?
Ashish Kumar,Eily Cournoyer,Leonard Naymagon
View Articletitled, Inflamed—HLH, MAS, or something else?
Too many white cells—TAM, JMML, or something else?
Alexandra Satty,Elliot Stieglitz,Nicole Kucine
View Articletitled, Too many white cells—TAM, JMML, or something else?
Where have all the platelets gone? HIT, DIC, or something else?
Rohith Jesudas,Clifford M. Takemoto
View Articletitled, Where have all the platelets gone? HIT, DIC, or something else?

Are We Personalizing MDS Therapy in 2023?

How to classify risk based on clinical and molecular modeling: integrating molecular markers in the risk assessment of myelodysplastic syndrome
Rena R. Xian
View Articletitled, How to classify risk based on clinical and molecular modeling: integrating molecular markers in the risk assessment of myelodysplastic syndrome
Next-generation therapy for lower-risk MDS
Marie Sébert
View Articletitled, Next-generation therapy for lower-risk MDS
Frontline treatment options for higher-risk MDS: can we move past azacitidine?
David A. Sallman,Zhuoer Xie
View Articletitled, Frontline treatment options for higher-risk MDS: can we move past azacitidine?
Mutational screening to improve the transplantation decision-making process in MDS
Evidence-Based Minireview
Alessia Campagna,Matteo G. Della Porta
View Articletitled, Mutational screening to improve the transplantation decision-making process in MDS

CAR T Cells in ALL: Bridge or Definitive Therapy?

Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL
Rebecca Epperly,Nirali N. Shah
View Articletitled, Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL
Stem cell transplantation for ALL: you've always got a donor, why not always use it?
David Shyr,Kara L. Davis,Alice Bertaina
View Articletitled, Stem cell transplantation for ALL: you've always got a donor, why not always use it?
Preventing relapse after CD19 CAR T-cell therapy for pediatric ALL: the role of transplant and enhanced CAR T cells
Aimee C. Talleur,Swati Naik,Stephen Gottschalk
View Articletitled, Preventing relapse after CD19 CAR T-cell therapy for pediatric ALL: the role of transplant and enhanced CAR T cells

Energizing the Red Cell: Pyruvate Kinase Activators for Treatment of Hereditary Hemolytic Anemias

Pyruvate kinase activators for treatment of pyruvate kinase deficiency
Rachael F. Grace
View Articletitled, Pyruvate kinase activators for treatment of pyruvate kinase deficiency
Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease
Julia Z. Xu,Gregory M. Vercellotti
View Articletitled, Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease
Pyruvate kinase activators: targeting red cell metabolism in thalassemia
Kevin H.M. Kuo
View Articletitled, Pyruvate kinase activators: targeting red cell metabolism in thalassemia
When should gene therapy be considered for transfusion-dependent β-thalassemia patients?
Evidence-Based Minireview
Cheryl Mensah,Sujit Sheth
View Articletitled, When should gene therapy be considered for transfusion-dependent β-thalassemia patients?

Goldilocks and Transplant Timing in Inherited Marrow Failure Syndromes: Too Early, Too Late, Just Right?

Clonal evolution in inherited marrow failure syndromes predicts disease progression
Kristen E. Schratz
View Articletitled, Clonal evolution in inherited marrow failure syndromes predicts disease progression
Minimal intensity conditioning strategies for bone marrow failure: is it time for “preventative” transplants?
Suneet Agarwal
View Articletitled, Minimal intensity conditioning strategies for bone marrow failure: is it time for “preventative” transplants?
Posttransplant complications in patients with marrow failure syndromes: are we improving long-term outcomes?
Zahra Hudda,Kasiani C. Myers
View Articletitled, Posttransplant complications in patients with marrow failure syndromes: are we improving long-term outcomes?

Graft-Versus-Host Disease: Is an Ounce of Prevention Worth a Pound of Cure?

Planning GvHD preemptive therapy: risk factors, biomarkers, and prognostic scores
Jacob Rozmus,John E. Levine,Kirk R. Schultz
View Articletitled, Planning GvHD preemptive therapy: risk factors, biomarkers, and prognostic scores
Novel approaches to acute graft-versus-host disease prevention
Benjamin Watkins,Muna Qayed
View Articletitled, Novel approaches to acute graft-versus-host disease prevention
Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies
Idoroenyi Amanam,Salman Otoukesh,Monzr M. Al Malki,Amandeep Salhotra
View Articletitled, Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies
Should posttransplant cyclophosphamide be considered standard of care for pediatric transplantation of acute leukemia?
Evidence-Based Minireview
Erin E. Doherty,Robert A. Krance
View Articletitled, Should posttransplant cyclophosphamide be considered standard of care for pediatric transplantation of acute leukemia?

Have We Optimized Therapy Yet for Patients with AML?

Improving long-term outcomes with intensive induction chemotherapy for patients with AML
Christoph Röllig
View Articletitled, Improving long-term outcomes with intensive induction chemotherapy for patients with AML
The approach of HMA plus VEN with or without BMT for all patients with AML
Heather J. Male,Tara L. Lin
View Articletitled, The approach of HMA plus VEN with or without BMT for all patients with AML
The future paradigm of HMA + VEN or targeted inhibitor approaches: sequencing or triplet combinations in AML therapy
Sangeetha Venugopal,Justin Watts
View Articletitled, The future paradigm of HMA + VEN or targeted inhibitor approaches: sequencing or triplet combinations in AML therapy

Hematologic Toxicity of Immunotherapies

Recognizing, defining, and managing CAR-T hematologic toxicities
Kai Rejeski,Marion Subklewe,Frederick L. Locke
View Articletitled, Recognizing, defining, and managing CAR-T hematologic toxicities
Checkpoint inhibitors
Michael H. Kroll
View Articletitled, Checkpoint inhibitors
Bispecific antibody therapies
Luiz Henrique de Assis,Daniel El Fassi,Martin Hutchings
View Articletitled, Bispecific antibody therapies

Hematologists and the Care of Pregnant Women

Identifying and treating iron deficiency anemia in pregnancy
Adam K. Lewkowitz,Methodius G. Tuuli
View Articletitled, Identifying and treating iron deficiency anemia in pregnancy
Management of pregnant women who have bleeding disorders
Andra H. James,Luis D. Pacheco,Barbara A. Konkle
View Articletitled, Management of pregnant women who have bleeding disorders
Prevention, diagnosis, and management of PE and DVT in pregnant women
Barry Kevane,Fionnuala Ní Áinle
View Articletitled, Prevention, diagnosis, and management of PE and DVT in pregnant women

Hematologists as Lifesavers: Inpatient Hematology Emergencies

How to avoid early mortality in acute promyelocytic leukemia
Oluwatobi Odetola,Martin S. Tallman
View Articletitled, How to avoid early mortality in acute promyelocytic leukemia
How to manage ITP with life-threatening bleeding
Jean M. Connors,Steven Fein
View Articletitled, How to manage ITP with life-threatening bleeding
Inpatient recognition and management of HLH
Adi Zoref-Lorenz,Martin Ellis,Michael B. Jordan
View Articletitled, Inpatient recognition and management of HLH

Hemostasis in Patients with Severe Liver Disease

How to assess hemostasis in patients with severe liver disease
Ton Lisman
View Articletitled, How to assess hemostasis in patients with severe liver disease
How to manage hemostasis in patients with liver disease during interventions
Lara N. Roberts
View Articletitled, How to manage hemostasis in patients with liver disease during interventions
How to manage splanchnic vein thrombosis in patients with liver disease
Nicoletta Riva,Walter Ageno
View Articletitled, How to manage splanchnic vein thrombosis in patients with liver disease
Direct oral anticoagulants to treat deep venous thrombosis and pulmonary embolism in patients with cirrhosis: are we there yet?
Evidence-Based Minireview
Amber Afzal,Jordan Schaefer
View Articletitled, Direct oral anticoagulants to treat deep venous thrombosis and pulmonary embolism in patients with cirrhosis: are we there yet?

Hot Topics in Blood Donation: Donor Risks and Social Justice

MSM and blood donation: shifting to individualized risk assessment
Mindy Goldman
View Articletitled, MSM and blood donation: shifting to individualized risk assessment
Clonal hematopoiesis in frequent whole blood donors
Darja Karpova
View Articletitled, Clonal hematopoiesis in frequent whole blood donors
T-cell lymphopenia in frequent volunteer platelet donors
Richard M. Kaufman
View Articletitled, T-cell lymphopenia in frequent volunteer platelet donors

How Can We Manage High-Risk Hematologic Malignancies in the Community?

Acute leukemias and complicated lymphomas: pearls to optimize management when patients stay local
Dipti Patel-Donnelly,Mitul Gandhi
View Articletitled, Acute leukemias and complicated lymphomas: pearls to optimize management when patients stay local
Multiple myeloma: a paradigm for blending community and academic care
Jesús G. Berdeja
View Articletitled, Multiple myeloma: a paradigm for blending community and academic care
Clinical research in the community
Ruemu Ejedafeta Birhiray,Maya Nicole Birhiray
View Articletitled, Clinical research in the community

How Do We Apply T-Cell Redirection Therapy for Multiple Myeloma? CAR T Cells and Bispecific Antibodies

Current use of bispecific antibodies to treat multiple myeloma
Holly Lee,Paola Neri,Nizar J. Bahlis
View Articletitled, Current use of bispecific antibodies to treat multiple myeloma
Current use of CAR T cells to treat multiple myeloma
Ross S. Firestone,Sham Mailankody
View Articletitled, Current use of CAR T cells to treat multiple myeloma
Managing side effects: guidance for use of immunotherapies in multiple myeloma
Emily C. Liang,Surbhi Sidana
View Articletitled, Managing side effects: guidance for use of immunotherapies in multiple myeloma

How Do We Calibrate Cellular Therapy for Lymphoma in 2023?

CAR T-cell therapy in aggressive lymphomas—identifying prognostic and predictive markers
Alberto Mussetti,Nicole Fabbri,Anna Sureda
View Articletitled, CAR T-cell therapy in aggressive lymphomas—identifying prognostic and predictive markers
Management of aggressive lymphoma after CAR T-cell therapy failure
Loretta J. Nastoupil,Swetha Kambhampati
View Articletitled, Management of aggressive lymphoma after CAR T-cell therapy failure
Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas
Ajay Major,Manali Kamdar
View Articletitled, Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas
Barriers to accessing cellular therapy for patients receiving care in community practices
Evidence-Based Minireview
Chijioke Nze,Christopher R. Flowers
View Articletitled, Barriers to accessing cellular therapy for patients receiving care in community practices

How Do We Enhance Results in Rare Hematologic Malignancies?

Langerhans cell histiocytosis: promises and caveats of targeted therapies in high-risk and CNS disease
Oussama Abla
View Articletitled, Langerhans cell histiocytosis: promises and caveats of targeted therapies in high-risk and CNS disease
Mastocytosis demystified
Scott Veitch,Deepti H. Radia
View Articletitled, Mastocytosis demystified
Amyloid consults do not have to be vexing
Anita D'Souza
View Articletitled, Amyloid consults do not have to be vexing

How Do We Extend Survival for Patients with CLL in 2023?

MRD-directed therapy in CLL: ready for prime time?
Joanna M. Rhodes,Carlos A. Lopez,Jacqueline C. Barrientos
View Articletitled, MRD-directed therapy in CLL: ready for prime time?
Dual-targeted regimens for the frontline treatment of CLL
Chaitra Ujjani
View Articletitled, Dual-targeted regimens for the frontline treatment of CLL
Richter transformation—is there light at the end of this tunnel?
Toby A. Eyre
View Articletitled, Richter transformation—is there light at the end of this tunnel?

How Do We Improve Outcomes in Relapsed and Refractory Multiple Myeloma in 2023?

A rational approach to functional high-risk myeloma
Francesca Gay,Giuseppe Bertuglia,Roberto Mina
View Articletitled, A rational approach to functional high-risk myeloma
Considerations for next therapy after anti-CD38 monoclonal antibodies used as first line
Monique Hartley-Brown,Ateh Zinkeng
View Articletitled, Considerations for next therapy after anti-CD38 monoclonal antibodies used as first line
Options at the time of relapse after anti-BCMA therapy
Beatrice Razzo,Alfred L. Garfall,Adam D. Cohen
View Articletitled, Options at the time of relapse after anti-BCMA therapy

How Do We Tackle Remaining Clinical Challenges in CML?

Accelerated-phase CML: de novo and transformed
Naranie Shanmuganathan,Timothy P. Hughes
View Articletitled, Accelerated-phase CML: de novo and transformed
Resistance mutations in CML and how we approach them
Simona Soverini
View Articletitled, Resistance mutations in CML and how we approach them
Atypical CML: diagnosis and treatment
Massimo Breccia
View Articletitled, Atypical CML: diagnosis and treatment

How Is the Management Paradigm Evolving for Hodgkin Lymphoma in 2023?

Hodgkin lymphoma treatment for older persons in the modern era
Andrew M. Evens,Marshall McKenna,Yun Kyoung Ryu Tiger,Jenica N. Upshaw
View Articletitled, Hodgkin lymphoma treatment for older persons in the modern era
Supplemental data
Management of limited-stage Hodgkin lymphoma
Taha Al-Juhaishi,Sairah Ahmed
View Articletitled, Management of limited-stage Hodgkin lymphoma
The optimal management of relapsed and refractory Hodgkin lymphoma: post–brentuximab and checkpoint inhibitor failure
Natalie S. Grover,Christopher Dittus,Astha Thakkar,Anne W. Beaven
View Articletitled, The optimal management of relapsed and refractory Hodgkin lymphoma: post–brentuximab and checkpoint inhibitor failure

Improving Outcomes for Individuals with Sickle Cell Disease: Are We Moving the Needle?

Using disease-modifying therapies in sickle cell disease
Parul Rai,Kenneth I. Ataga
View Articletitled, Using disease-modifying therapies in sickle cell disease
The range of haploidentical transplant protocols in sickle cell disease: all haplos are not created equally
Adetola A. Kassim,Michael R. DeBaun
View Articletitled, The range of haploidentical transplant protocols in sickle cell disease: all haplos are not created equally
Gene therapy for sickle cell disease
Alexis Leonard,John F. Tisdale
View Articletitled, Gene therapy for sickle cell disease

Inherited Bone Marrow Failure Syndromes: from Pediatrics to Adult

When to consider inherited marrow failure syndromes in adults
Fernanda Gutierrez-Rodrigues,Bhavisha A. Patel,Emma M. Groarke
View Articletitled, When to consider inherited marrow failure syndromes in adults
Management of Fanconi anemia beyond childhood
Timothy S. Olson
View Articletitled, Management of Fanconi anemia beyond childhood
Clinical manifestations of telomere biology disorders in adults
Marena R. Niewisch,Fabian Beier,Sharon A. Savage
View Articletitled, Clinical manifestations of telomere biology disorders in adults

Not Kids Anymore and Not Adults Yet: How Do We Treat Adolescent and Young Adult (AYA) Patients with ALL?

Acute lymphoblastic leukemia in young adults: which up-front treatment?
John C. Molina,Seth Rotz
View Articletitled, Acute lymphoblastic leukemia in young adults: which up-front treatment?
Adolescents and young adults (AYAs) vs pediatric patients: survival, risks, and barriers to enrollment
Sanyukta K. Janardan,Tamara P. Miller
View Articletitled, Adolescents and young adults (AYAs) vs pediatric patients: survival, risks, and barriers to enrollment
Challenges to successful outcomes in AYAs with ALL and potential solutions
Annabelle Anandappa,Emily Curran
View Articletitled, Challenges to successful outcomes in AYAs with ALL and potential solutions

Ongoing Challenges in the Management of VTE

The dos, don'ts, and nuances of thrombophilia testing
Thita Chiasakul,Kenneth A. Bauer
View Articletitled, The dos, don'ts, and nuances of thrombophilia testing
Provoked vs minimally provoked vs unprovoked VTE: does it matter?
Cecilia Becattini,Ludovica Anna Cimini
View Articletitled, Provoked vs minimally provoked vs unprovoked VTE: does it matter?
How to diagnose and manage antiphospholipid syndrome
Anne Hubben,Keith R. McCrae
View Articletitled, How to diagnose and manage antiphospholipid syndrome
Should older patients with low weight and CKD receive full-dose DOACs for treatment of acute proximal DVT?
Evidence-Based Minireview
Nicolas Gallastegui,Camila Masias
View Articletitled, Should older patients with low weight and CKD receive full-dose DOACs for treatment of acute proximal DVT?

The Iron Revolution!

Sex, lies, and iron deficiency: a call to change ferritin reference ranges
Kylee Martens,Thomas G. DeLoughery
View Articletitled, Sex, lies, and iron deficiency: a call to change ferritin reference ranges
IV iron formulations and use in adults
Layla Van Doren,Michael Auerbach
View Articletitled, IV iron formulations and use in adults
Intravenous iron therapy in pediatrics: who should get it and when is the right time?
Clay T. Cohen,Jacquelyn M. Powers
View Articletitled, Intravenous iron therapy in pediatrics: who should get it and when is the right time?
Incidence, mechanism, and consequences of IV iron–induced hypophosphatemia
Evidence-Based Minireview
Kylee L. Martens,Myles Wolf
View Articletitled, Incidence, mechanism, and consequences of IV iron–induced hypophosphatemia

Transfusion Support in Sickle Cell Disease

Managing pregnancy in patients with sickle cell disease from a transfusion perspective
Anoosha Habibi,Alexandra Benachi,Edouard Lecarpentier
View Articletitled, Managing pregnancy in patients with sickle cell disease from a transfusion perspective
Logistics, risks, and benefits of automated red blood cell exchange for patients with sickle cell disease
Shannon Kelly
View Articletitled, Logistics, risks, and benefits of automated red blood cell exchange for patients with sickle cell disease
Alloimmunization and hyperhemolysis in sickle cell disease
France Pirenne,Corinne Pondarré
View Articletitled, Alloimmunization and hyperhemolysis in sickle cell disease

What Are the Advances in Myeloproliferative Neoplasms Affecting Management?

Cytoreduction for ET and PV: who, what, when, and how?
Douglas Tremblay
View Articletitled, Cytoreduction for ET and PV: who, what, when, and how?
Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations
Harinder Gill,Garret M. K. Leung,Yok-Lam Kwong
View Articletitled, Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations
Are transplant indications changing for myelofibrosis?
Jeanne Palmer
View Articletitled, Are transplant indications changing for myelofibrosis?

What Are Treatment Options for Patients with Relapsed, Refractory, or Persistent AML?

Understanding differential technologies for detection of MRD and how to incorporate into clinical practice
Jacqueline Cloos,Lok Lam Ngai,Michael Heuser
View Articletitled, Understanding differential technologies for detection of MRD and how to incorporate into clinical practice
Novel immunotherapies in the treatment of AML: is there hope?
Marion Subklewe,Veit Bücklein,David Sallman,Naval Daver
View Articletitled, Novel immunotherapies in the treatment of AML: is there hope?
Novel therapies upon failure of HMA plus venetoclax
Onyee Chan,Alison R. Walker
View Articletitled, Novel therapies upon failure of HMA plus venetoclax

What Makes a Good Transplant Recipient? Putting the Puzzle Pieces Together

How old is too old? Frailty and geriatric assessments of older patients undergoing allogeneic HCT
Reena V. Jayani
View Articletitled, How old is too old? Frailty and geriatric assessments of older patients undergoing allogeneic HCT
The sum of the parts: what we can and cannot learn from comorbidity scores in allogeneic transplantation
Roni Shouval,Joshua A. Fein
View Articletitled, The sum of the parts: what we can and cannot learn from comorbidity scores in allogeneic transplantation
Approaches to optimize outcomes in transplant recipients
Asmita Mishra
View Articletitled, Approaches to optimize outcomes in transplant recipients
What makes a pediatric or young adult patient an appropriate transplant candidate?
Evidence-Based Minireview
Monica S. Thakar,Mohamed L. Sorror
View Articletitled, What makes a pediatric or young adult patient an appropriate transplant candidate?

Why Am I Getting Paged at 2 AM? Microangiopathic Emergencies

Labor and delivery: DIC, HELLP, preeclampsia
Juliana Perez Botero,Jennifer Jury McIntosh
View Articletitled, Labor and delivery: DIC, HELLP, preeclampsia
Medical consult: aHUS, TTP? How to distinguish and what to do
Charlotte M. Story,Gloria F Gerber,Shruti Chaturvedi
View Articletitled, Medical consult: aHUS, TTP? How to distinguish and what to do
Consumptive coagulopathy in the ICU
Andrew Retter,Beverley J. Hunt
View Articletitled, Consumptive coagulopathy in the ICU
All Issues
Targeted medical therapies for vascular anomalies
T-cell–based therapies for treating relapsed or refractory mantle cell lymphoma
Transplant in ALL: who, when, and how?
Ph− ALL: immunotherapy in upfront treatment
Ph+ ALL: new approaches for upfront therapy
  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal